EFFECTS OF PRAMLINTIDE IN ADOLESCENT PATIENTS WITH TYPE 1 DIABETES

普兰林肽对青少年 1 型糖尿病患者的影响

• 批准号: 7605144
• 负责人: CHRISTOPHER M KISHIYAMA
• 金额: $ 0.33万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605144
• 关键词: Adolescent; Adult; Age-Years; Beta Cell; Blood Glucose; Caring; Computer Retrieval of Information on Scientific Projects Database; Diabetes Mellitus; Funding; Gastric Emptying; Glucagon; Grant; Hormones; Hyperglycemia; Institution; Insulin; Insulin Resistance; Insulin-Dependent Diabetes Mellitus; Neurosecretory Systems; Patients; Pramlintide; Puberty; Replacement Therapy; Research; Research Personnel; Resources; Risk; Secondary to; Source; United States Food and Drug Administration; United States National Institutes of Health; day; glycemic control; improved; islet amyloid polypeptide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Despite improvements in diabetes care and insulin therapy, patients with type 1 diabetes (TID) continue to have significant post-prandial blood glucose excursions. These periods of hyperglycemia correlate with long-term complications associated with diabetes. Amylin, a natural neuroendocrine hormone secreted by the beta cell, improves glycemic control by regulating glucagon secretion and slowing gastric emptying. Replacement therapy is now FDA approved for adult patients with T1D in the form of pramlintide, a synthetic form of amylin. Amylin is not yet approved for use in adolescents under 16 years of age. We hypothesize this potential replacement therapy would be a useful adjunct in adolescent patients who are insulin resistant secondary to puberty and therefore at greater risk of post-prandial hyperglycemia. Our study proposes a 36-day trial investigating pramlintide effects in adolescent patients with sub-optimally controlled T1D.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 尽管糖尿病护理和胰岛素治疗有所改善，但1型糖尿病（TID）患者仍具有明显的餐后血糖散发。 这些高血糖的时期与与糖尿病有关的长期并发症相关。 氨基蛋白是β细胞分泌的一种天然神经内分泌激素，可通过调节胰高血糖素的分泌和减慢胃排空来改善血糖控制。 现在，以Pramlintide（一种合成的链淀粉形式）形式为成人T1D患者批准了FDA批准的FDA。氨基蛋白尚未批准在16岁以下的青少年中使用。我们假设这种潜在的替代疗法将是青春期抗胰岛素耐青春期的胰岛素耐药蛋白的有用辅助手段，因此有更大的后野性高血糖症的风险。 我们的研究提出了一项为期36天的试验，调查了青少年次级控制T1D的青少年患者的pramlintide效应。